Tempus AI (NASDAQ:TEM) has been on fire, drawing massive interest from institutional investors in the fourth quarter of 2024 as big funds piled into the AI-powered precision medicine company.
Since going public in June 2024, Tempus has quickly become a favorite among investors. The number of institutional filings jumped from 89 to 174 in just three quarters, and the total number of shares heldexcluding optionshas climbed significantly.
Cathie Wood's ARK Investment Management was one of the most aggressive buyers, boosting its stake by 132% from Q3 and an eye-popping 956% from Q2, bringing its holdings to $186.3 million. JPMorgan Chase (NYSE:JPM) made an even bigger move, adding 1,650,096 sharesa staggering 43424% increase in just one quarter. UBS Group (NYSE:UBS) wasn't far behind, increasing its stake by 6524% (786,025 shares).
And they weren't the only ones. Barclays (NYSE:BCS) raised its position by 3675%, while Goldman Sachs (NYSE:GS) and Morgan Stanley (NYSE:MS) increased theirs by 129% and 40%, respectively. Meanwhile, BlackRock (NYSE:BLK), Bank of New York Mellon (NYSE:BK), and Ken Griffin's Citadel Advisors all took fresh positions, joining 70 other funds in making a big bet on Tempus AI.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.